Total Valuation
AstraZeneca has a market cap or net worth of $4.58T. The enterprise value is $240.56K.
Market Cap$4.58T
Enterprise Value$240.56K
Share Statistics
AstraZeneca has 1,551,024,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,551,024,500
Owned by Insiders0.03%
Owned by Institutions1.99%
Financial Efficiency
AstraZeneca’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 13.04%.
Return on Equity (ROE)0.21
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)13.04%
Return on Capital Employed (ROCE)0.16
Revenue Per Employee611.23K
Profits Per Employee129.05K
Employee Count96,100
Asset Turnover0.51
Inventory Turnover1.62
Valuation Ratios
The current PE Ratio of AstraZeneca is 25.3. AstraZeneca’s PEG ratio is 0.58.
PE Ratio25.3
PS Ratio4.90
PB Ratio5.91
Price to Fair Value5.91
Price to FCF33.17
Price to Operating Cash Flow19.22
PEG Ratio0.58
Income Statement
In the last 12 months, AstraZeneca had revenue of 58.74B and earned 10.22B in profits. Earnings per share was 6.60.
Revenue58.74B
Gross Profit48.11B
Operating Income13.74B
Pretax Income12.40B
Net Income10.22B
EBITDA19.83B
Earnings Per Share (EPS)6.60
Cash Flow
In the last 12 months, operating cash flow was 13.74B and capital expenditures -5.31B, giving a free cash flow of 8.43B billion.
Operating Cash Flow13.74B
Free Cash Flow8.43B
Free Cash Flow per Share5.44
Dividends & Yields
AstraZeneca pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.32
52-Week Price Change7.97%
50-Day Moving Average3.13K
200-Day Moving Average3.21K
Relative Strength Index (RSI)―
Average Volume (3m)120.00
Important Dates
AstraZeneca upcoming earnings date is Oct 30, 2026, Before Open (Confirmed).
Last Earnings DateJul 27, 2026
Next Earnings DateOct 30, 2026
Ex-Dividend Date―
Financial Position
AstraZeneca as a current ratio of 0.94, with Debt / Equity ratio of 64.10%
Current Ratio0.94
Quick Ratio0.72
Debt to Market Cap0.10
Net Debt to EBITDA1.21
Interest Coverage Ratio8.11
Taxes
In the past 12 months, AstraZeneca has paid 2.17B in taxes.
Income Tax2.17B
Effective Tax Rate0.17
Enterprise Valuation
AstraZeneca EV to EBITDA ratio is 15.71, with an EV/FCF ratio of 35.93.
EV to Sales5.30
EV to EBITDA15.71
EV to Free Cash Flow35.93
EV to Operating Cash Flow21.37
Balance Sheet
AstraZeneca has $4.99B in cash and marketable securities with $32.41B in debt, giving a net cash position of -$27.41B billion.
Cash & Marketable Securities$4.99B
Total Debt$32.41B
Net Cash-$27.41B
Net Cash Per Share-$17.67
Tangible Book Value Per Share-$6.69
Margins
Gross margin is 79.27%, with operating margin of 23.40%, and net profit margin of 17.41%.
Gross Margin79.27%
Operating Margin23.40%
Pretax Margin21.11%
Net Profit Margin17.41%
EBITDA Margin33.76%
EBIT Margin24.00%
Analyst Forecast
The average price target for AstraZeneca is $3,757.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$3,757.57
Price Target Upside26.76% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast-1.15%
EPS Growth Forecast13.89%